Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 506

1.

Degradome of soluble ADAM10 and ADAM17 metalloproteases.

Scharfenberg F, Helbig A, Sammel M, Benzel J, Schlomann U, Peters F, Wichert R, Bettendorff M, Schmidt-Arras D, Rose-John S, Moali C, Lichtenthaler SF, Pietrzik CU, Bartsch JW, Tholey A, Becker-Pauly C.

Cell Mol Life Sci. 2019 Jun 17. doi: 10.1007/s00018-019-03184-4. [Epub ahead of print]

PMID:
31209506
2.

Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation.

Pavlenko E, Cabron AS, Arnold P, Dobert JP, Rose-John S, Zunke F.

Int J Mol Sci. 2019 May 4;20(9). pii: E2198. doi: 10.3390/ijms20092198.

3.

Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3.

Servais FA, Kirchmeyer M, Hamdorf M, Minoungou NWE, Rose-John S, Kreis S, Haan C, Behrmann I.

Mol Ther Nucleic Acids. 2019 Jun 7;16:419-433. doi: 10.1016/j.omtn.2019.03.007. Epub 2019 Apr 2.

4.

ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury.

Sommer D, Corstjens I, Sanchez S, Dooley D, Lemmens S, Van Broeckhoven J, Bogie J, Vanmierlo T, Vidal PM, Rose-John S, Gou-Fabregas M, Hendrix S.

Brain Behav Immun. 2019 Mar 6. pii: S0889-1591(18)31201-7. doi: 10.1016/j.bbi.2019.02.032. [Epub ahead of print]

5.

ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ.

EMBO Mol Med. 2019 Apr;11(4). pii: e9976. doi: 10.15252/emmm.201809976.

6.

Correction to: A new multiple trauma model of the mouse.

Fitschen-Oestern S, Lippross S, Klueter T, Weuster M, Varoga D, Tohidnezhad M, Pufe T, Rose-John S, Andruszkow H, Hildebrand F, Steubesand N, Seekamp A, Neunaber C.

BMC Musculoskelet Disord. 2019 Feb 11;20(1):72. doi: 10.1186/s12891-018-2330-1. No abstract available.

7.

Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates.

Paige E, Clément M, Lareyre F, Sweeting M, Raffort J, Grenier C, Finigan A, Harrison J, Peters JE, Sun BB, Butterworth AS, Harrison SC, Bown MJ, Lindholt JS, Badger SA, Kullo IJ, Powell J, Norman PE, Scott DJA, Bailey MA, Rose-John S, Danesh J, Freitag DF, Paul DS, Mallat Z.

Circ Genom Precis Med. 2019 Feb;12(2):e002413. doi: 10.1161/CIRCGEN.118.002413.

8.

Impaired mechanical, heat, and cold nociception in a murine model of genetic TACE/ADAM17 knockdown.

Quarta S, Mitrić M, Kalpachidou T, Mair N, Schiefermeier-Mach N, Andratsch M, Qi Y, Langeslag M, Malsch P, Rose-John S, Kress M.

FASEB J. 2019 Mar;33(3):4418-4431. doi: 10.1096/fj.201801901R. Epub 2018 Dec 26.

9.

Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.

Prenissl N, Lokau J, Rose-John S, Haybaeck J, Garbers C.

Cytokine. 2019 Feb;114:1-5. doi: 10.1016/j.cyto.2018.11.023. Epub 2018 Dec 14.

10.

Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.

Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J.

Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9.

11.

Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells.

Cabron AS, El Azzouzi K, Boss M, Arnold P, Schwarz J, Rosas M, Dobert JP, Pavlenko E, Schumacher N, Renné T, Taylor PR, Linder S, Rose-John S, Zunke F.

J Immunol. 2018 Nov 15;201(10):3106-3118. doi: 10.4049/jimmunol.1701556. Epub 2018 Oct 24.

12.

Correction: The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.

Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K, Moriggl R.

Oncotarget. 2018 Sep 18;9(73):33865. doi: 10.18632/oncotarget.26156. eCollection 2018 Sep 18.

13.

Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure.

Armacki M, Trugenberger AK, Ellwanger AK, Eiseler T, Schwerdt C, Bettac L, Langgartner D, Azoitei N, Halbgebauer R, Groß R, Barth T, Lechel A, Walter BM, Kraus JM, Wiegreffe C, Grimm J, Scheffold A, Schneider MR, Peuker K, Zeißig S, Britsch S, Rose-John S, Vettorazzi S, Wolf E, Tannapfel A, Steinestel K, Reber SO, Walther P, Kestler HA, Radermacher P, Barth TF, Huber-Lang M, Kleger A, Seufferlein T.

J Clin Invest. 2018 Nov 1;128(11):5056-5072. doi: 10.1172/JCI97912. Epub 2018 Oct 15.

14.

Laboratory diagnostics of murine blood for detection of mouse cytomegalovirus (MCMV)-induced hepatitis.

Stahl FR, Jung R, Jazbutyte V, Ostermann E, Tödter S, Brixel R, Kemmer A, Halle S, Rose-John S, Messerle M, Arck PC, Brune W, Renné T.

Sci Rep. 2018 Oct 4;8(1):14823. doi: 10.1038/s41598-018-33167-7.

15.

Mutations in Craniosynostosis Patients Cause Defective Interleukin-11 Receptor Maturation and Drive Craniosynostosis-like Disease in Mice.

Agthe M, Brügge J, Garbers Y, Wandel M, Kespohl B, Arnold P, Flynn CM, Lokau J, Aparicio-Siegmund S, Bretscher C, Rose-John S, Waetzig GH, Putoczki T, Grötzinger J, Garbers C.

Cell Rep. 2018 Oct 2;25(1):10-18.e5. doi: 10.1016/j.celrep.2018.09.005.

16.

Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice.

Aden K, Bartsch K, Dahl J, Reijns MAM, Esser D, Sheibani-Tezerji R, Sinha A, Wottawa F, Ito G, Mishra N, Knittler K, Burkholder A, Welz L, van Es J, Tran F, Lipinski S, Kakavand N, Boeger C, Lucius R, von Schoenfels W, Schafmayer C, Lenk L, Chalaris A, Clevers H, Röcken C, Kaleta C, Rose-John S, Schreiber S, Kunkel T, Rabe B, Rosenstiel P.

Gastroenterology. 2019 Jan;156(1):145-159.e19. doi: 10.1053/j.gastro.2018.09.047. Epub 2018 Sep 28.

17.

Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells.

Lücke K, Yan I, Krohn S, Volmari A, Klinge S, Schmid J, Schumacher V, Steinmetz OM, Rose-John S, Mittrücker HW.

PLoS One. 2018 Aug 31;13(8):e0203395. doi: 10.1371/journal.pone.0203395. eCollection 2018.

18.

Interleukin 6 trans-signalling and risk of future cardiovascular events.

Ziegler L, Gajulapuri A, Frumento P, Bonomi A, Wallén H, de Faire U, Rose-John S, Gigante B.

Cardiovasc Res. 2019 Jan 1;115(1):213-221. doi: 10.1093/cvr/cvy191.

PMID:
30052808
19.

Differing Outcome of Experimental Autoimmune Encephalitis in Macrophage/Neutrophil- and T Cell-Specific gp130-Deficient Mice.

Holz K, Prinz M, Brendecke SM, Hölscher A, Deng F, Mitrücker HW, Rose-John S, Hölscher C.

Front Immunol. 2018 May 2;9:836. doi: 10.3389/fimmu.2018.00836. eCollection 2018.

20.

Interleukin-6: designing specific therapeutics for a complex cytokine.

Garbers C, Heink S, Korn T, Rose-John S.

Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4. Review.

PMID:
29725131
21.

The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.

Fuchslocher Chico J, Falk-Paulsen M, Luzius A, Saggau C, Ruder B, Bolik J, Schmidt-Arras D, Linkermann A, Becker C, Rosenstiel P, Rose-John S, Adam D.

Oncotarget. 2018 Feb 5;9(16):12941-12958. doi: 10.18632/oncotarget.24410. eCollection 2018 Feb 27.

22.

Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma.

Kaiser K, Prystaz K, Vikman A, Haffner-Luntzer M, Bergdolt S, Strauss G, Waetzig GH, Rose-John S, Ignatius A.

Naunyn Schmiedebergs Arch Pharmacol. 2018 May;391(5):523-536. doi: 10.1007/s00210-018-1483-7. Epub 2018 Mar 1.

23.

ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S.

J Exp Med. 2018 Apr 2;215(4):1205-1225. doi: 10.1084/jem.20171696. Epub 2018 Feb 22.

24.

BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K.

J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.

25.

Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.

Garbers C, Rose-John S.

Methods Mol Biol. 2018;1725:127-140. doi: 10.1007/978-1-4939-7568-6_11.

PMID:
29322414
26.

The ADAM17 Metalloproteinase Maintains Arterial Elasticity.

Nicolaou A, Northoff BH, Zhao Z, Kohlmaier A, Sass K, Rose-John S, Steffens S, Weber C, Teupser D, Holdt LM.

Thromb Haemost. 2018 Jan;118(1):210-213. doi: 10.1160/TH17-07-0494. Epub 2018 Jan 5. No abstract available.

PMID:
29304540
27.

The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma.

Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach JP, Helm O, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzel P, Schneider G, Saur D, Schäfer H, Sebens S.

Oncoimmunology. 2017 Oct 26;7(1):e1368603. doi: 10.1080/2162402X.2017.1368603. eCollection 2017.

28.

Suppressor of Cytokine Signaling 3 in Macrophages Prevents Exacerbated Interleukin-6-Dependent Arginase-1 Activity and Early Permissiveness to Experimental Tuberculosis.

Schmok E, Abad Dar M, Behrends J, Erdmann H, Rückerl D, Endermann T, Heitmann L, Hessmann M, Yoshimura A, Rose-John S, Scheller J, Schaible UE, Ehlers S, Lang R, Hölscher C.

Front Immunol. 2017 Nov 10;8:1537. doi: 10.3389/fimmu.2017.01537. eCollection 2017.

29.

Mucus Detachment by Host Metalloprotease Meprin β Requires Shedding of Its Inactive Pro-form, which Is Abrogated by the Pathogenic Protease RgpB.

Wichert R, Ermund A, Schmidt S, Schweinlin M, Ksiazek M, Arnold P, Knittler K, Wilkens F, Potempa B, Rabe B, Stirnberg M, Lucius R, Bartsch JW, Nikolaus S, Falk-Paulsen M, Rosenstiel P, Metzger M, Rose-John S, Potempa J, Hansson GC, Dempsey PJ, Becker-Pauly C.

Cell Rep. 2017 Nov 21;21(8):2090-2103. doi: 10.1016/j.celrep.2017.10.087.

30.

A new multiple trauma model of the mouse.

Fitschen-Oestern S, Lippross S, Klueter T, Weuster M, Varoga D, Tohidnezhad M, Pufe T, Rose-John S, Andruszkow H, Hildebrand F, Steubesand N, Seekamp A, Neunaber C.

BMC Musculoskelet Disord. 2017 Nov 21;18(1):468. doi: 10.1186/s12891-017-1813-9. Erratum in: BMC Musculoskelet Disord. 2019 Feb 11;20(1):72.

31.

Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing.

Prystaz K, Kaiser K, Kovtun A, Haffner-Luntzer M, Fischer V, Rapp AE, Liedert A, Strauss G, Waetzig GH, Rose-John S, Ignatius A.

Am J Pathol. 2018 Feb;188(2):474-490. doi: 10.1016/j.ajpath.2017.10.011. Epub 2017 Nov 13.

32.

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.

Sobotta S, Raue A, Huang X, Vanlier J, Jünger A, Bohl S, Albrecht U, Hahnel MJ, Wolf S, Mueller NS, D'Alessandro LA, Mueller-Bohl S, Boehm ME, Lucarelli P, Bonefas S, Damm G, Seehofer D, Lehmann WD, Rose-John S, van der Hoeven F, Gretz N, Theis FJ, Ehlting C, Bode JG, Timmer J, Schilling M, Klingmüller U.

Front Physiol. 2017 Oct 9;8:775. doi: 10.3389/fphys.2017.00775. eCollection 2017.

33.

Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.

Bender L, Weidmann H, Rose-John S, Renné T, Long AT.

Front Immunol. 2017 Sep 15;8:1115. doi: 10.3389/fimmu.2017.01115. eCollection 2017. Review.

34.

Cancer-associated mutations in the canonical cleavage site do not influence CD99 shedding by the metalloprotease meprin β but alter cell migration in vitro.

Bedau T, Schumacher N, Peters F, Prox J, Arnold P, Koudelka T, Helm O, Schmidt F, Rabe B, Jentzsch M, Rosenstiel P, Sebens S, Tholey A, Rose-John S, Becker-Pauly C.

Oncotarget. 2017 Jul 4;8(33):54873-54888. doi: 10.18632/oncotarget.18966. eCollection 2017 Aug 15.

35.

Frontline Science: Proliferation of Ly6C+ monocytes during urinary tract infections is regulated by IL-6 trans-signaling.

Dixit A, Bottek J, Beerlage AL, Schuettpelz J, Thiebes S, Brenzel A, Garbers C, Rose-John S, Mittrücker HW, Squire A, Engel DR.

J Leukoc Biol. 2018 Jan;103(1):13-22. doi: 10.1189/jlb.3HI0517-198R. Epub 2017 Dec 28.

PMID:
28882904
36.

The role of ADAM17 in the T-cell response against bacterial pathogens.

Link MA, Lücke K, Schmid J, Schumacher V, Eden T, Rose-John S, Mittrücker HW.

PLoS One. 2017 Sep 6;12(9):e0184320. doi: 10.1371/journal.pone.0184320. eCollection 2017.

37.

Proteolytic steps within signaling cascades make these signaling pathways irreversible.

Rose-John S.

Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2057-2058. doi: 10.1016/j.bbamcr.2017.08.007. Epub 2017 Aug 24. No abstract available.

38.

The shedding protease ADAM17: Physiology and pathophysiology.

Zunke F, Rose-John S.

Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070. doi: 10.1016/j.bbamcr.2017.07.001. Epub 2017 Jul 11. Review.

39.

The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.

Rose-John S.

Clin Pharmacol Ther. 2017 Oct;102(4):591-598. doi: 10.1002/cpt.782. Epub 2017 Jul 29. Review.

PMID:
28675418
40.

Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.

Kammoun HL, Allen TL, Henstridge DC, Kraakman MJ, Peijs L, Rose-John S, Febbraio MA.

PLoS One. 2017 Jun 20;12(6):e0179099. doi: 10.1371/journal.pone.0179099. eCollection 2017.

41.

Interleukin-6 Family Cytokines.

Rose-John S.

Cold Spring Harb Perspect Biol. 2018 Feb 1;10(2). pii: a028415. doi: 10.1101/cshperspect.a028415. Review.

PMID:
28620096
42.

The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Rose-John S, Winthrop K, Calabrese L.

Nat Rev Rheumatol. 2017 Jul;13(7):399-409. doi: 10.1038/nrrheum.2017.83. Epub 2017 Jun 15. Review.

PMID:
28615731
43.

Effect of Abdominal Ultrasound on Clinical Care, Outcomes, and Resource Use Among Children With Blunt Torso Trauma: A Randomized Clinical Trial.

Holmes JF, Kelley KM, Wootton-Gorges SL, Utter GH, Abramson LP, Rose JS, Tancredi DJ, Kuppermann N.

JAMA. 2017 Jun 13;317(22):2290-2296. doi: 10.1001/jama.2017.6322.

44.

Interleukin 6 trans-signaling regulates basal synaptic transmission and sensitivity to pentylenetetrazole-induced seizures in mice.

Cuevas-Olguin R, Esquivel-Rendon E, Vargas-Mireles J, Garcia-Oscos F, Miranda-Morales M, Salgado H, Rose-John S, Atzori M.

Synapse. 2017 Sep;71(9). doi: 10.1002/syn.21984. Epub 2017 May 13.

PMID:
28481031
45.

IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling.

Timper K, Denson JL, Steculorum SM, Heilinger C, Engström-Ruud L, Wunderlich CM, Rose-John S, Wunderlich FT, Brüning JC.

Cell Rep. 2017 Apr 11;19(2):267-280. doi: 10.1016/j.celrep.2017.03.043.

46.

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, Diamanti MA, Linder M, Timelthaler G, Dienes HP, Kenner L, Wrba F, Prager GW, Rose-John S, Eferl R, Liguori G, Botti G, Martinelli E, Greten FR, Ciardiello F, Sibilia M.

Gastroenterology. 2017 Jul;153(1):178-190.e10. doi: 10.1053/j.gastro.2017.03.053. Epub 2017 Apr 9.

47.

The balance between Treg and TH17 cells: CD11b and interleukin-6.

Garbers C, Rose-John S.

Eur J Immunol. 2017 Apr;47(4):629-632. doi: 10.1002/eji.201746988.

48.

Corrigendum: Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, Husterer V, Croxford AL, Möller-Hackbarth K, Bartsch HS, Sotlar K, Krebs S, Regen T, Blum H, Hemmer B, Misgeld T, Wunderlich TF, Hidalgo J, Oukka M, Rose-John S, Schmidt-Supprian M, Waisman A, Korn T.

Nat Immunol. 2017 Mar 22;18(4):474. doi: 10.1038/ni0417-474b. No abstract available.

PMID:
28323263
49.

Instructive Role of the Microenvironment in Preventing Renal Fibrosis.

Matsumoto K, Xavier S, Chen J, Kida Y, Lipphardt M, Ikeda R, Gevertz A, Caviris M, Hatzopoulos AK, Kalajzic I, Dutton J, Ratliff BB, Zhao H, Darzynkiewicz Z, Rose-John S, Goligorsky MS.

Stem Cells Transl Med. 2017 Mar;6(3):992-1005. doi: 10.5966/sctm.2016-0095. Epub 2016 Oct 5.

50.

Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling.

Arnold P, Boll I, Rothaug M, Schumacher N, Schmidt F, Wichert R, Schneppenheim J, Lokau J, Pickhinke U, Koudelka T, Tholey A, Rabe B, Scheller J, Lucius R, Garbers C, Rose-John S, Becker-Pauly C.

Sci Rep. 2017 Mar 9;7:44053. doi: 10.1038/srep44053.

Supplemental Content

Loading ...
Support Center